follow us:Google+ FacebookLinkedInTwitterRSS Feeds

advertisement

Eatontown medical tech developer reaches agreement

By

Back to Top Comments Email Print

Latest News

advertisement

An Eatontown-based developer of medical cellular technologies Wednesday announced it has a deal in place to develop cancer-fighting drug delivery methods.

American CryoStem Corporation said in a news release that it has initial agreements with UHV Techologies Inc.’s nanoRANCH division to work on drugs that focus on cancer treatments that utilize adult stem cells.

"We are noticing a sharp increase in demand for our cutting-edge clinically prepared cells and ancillary products for use in scientific development." Anthony Dudzinski, American CryoStem’s chief operating officer, said in the release.

The collaboration will use American CryoStem’s ATCELL products.

"Accurate targeting of pharmaceuticals is a continuing hurdle in drug delivery, and particularly important are selectivity and specificity of anticancer agents," Dr. Dan Dimitrijevich of nanoRANCH said in the release.

ALSO ON NJBIZ:

Be careful: For legal reasons, ACA-prompted wellness programs must be structured carefully

Top 10 rankings of New Jersey's best places for homeownership

Jersey Shore real estate agencies merge

Share This Story On:
Eric Strauss

Eric Strauss

Eric Strauss is the digital content editor for NJBIZ. He has been a reporter and editor for newspapers in New Jersey and Pennsylvania, as well as for a number of websites. You can contact him at erics@njbiz.com or @acerimrat on Twitter.

advertisement

Comments


Be the first to comment.



Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
     View Comment Policy

Advanced search
Sponsored by
advertisement
  
  
advertisement
  
  
advertisement
Back to Top